Literature DB >> 7606731

LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.

M de Arruda1, C A Cocchiaro, C M Nelson, C M Grinnell, B Janssen, A Haupt, T Barlozzari.   

Abstract

LU103793 (NSC D-669356) is a new synthetic derivative of Dolastatin 15, an antiproliferative compound which was isolated from the mollusk Dolabella auricularia. Like Dolastatin 15, LU103793 is highly cytotoxic in vitro (IC50 = 0.1 nM). To investigate the mechanism of action of LU103793, we used a combination of biochemical and cellular methods. Turbidity assays with bovine brain microtubules demonstrated that LU103793 inhibits microtubule polymerization in a concentration-dependent manner (IC50 = 7 microM). Treatment with this compound also induced depolymerization of preassembled microtubules. Cell cycle analysis of tumor cell lines treated with LU103793 indicated a block in the G2-M phase. At the cellular level, it induced depolymerization of microtubules in interphase cells and development of abnormal spindles and chromosome distribution in mitotic cells. Although these effects are very similar to the cellular alterations caused by vinblastine, LU103793 does not inhibit vinblastine binding to unpolymerized tubulin in vitro. Our results suggest that LU103793 exerts its cytotoxic activity primarily through disruption of microtubule organization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606731

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Application of a water-soluble pyridyl disulfide amine linker for use in Cu-free click bioconjugation.

Authors:  Joshua D Thomas; Terrence R Burke
Journal:  Tetrahedron Lett       Date:  2011-08-17       Impact factor: 2.415

3.  Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity.

Authors:  Ruoli Bai; Michael C Edler; Peter L Bonate; Terry D Copeland; George R Pettit; Richard F Ludueña; Ernest Hamel
Journal:  Mol Pharmacol       Date:  2008-10-16       Impact factor: 4.436

4.  (-)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds inducing the formation of morphologically similar tubulin spirals but binding apparently to two distinct sites on tubulin.

Authors:  Ruoli Bai; Ernest Hamel
Journal:  Arch Biochem Biophys       Date:  2016-06-13       Impact factor: 4.013

Review 5.  Bioactive peptides and depsipeptides with anticancer potential: sources from marine animals.

Authors:  Guadalupe-Miroslava Suarez-Jimenez; Armando Burgos-Hernandez; Josafat-Marina Ezquerra-Brauer
Journal:  Mar Drugs       Date:  2012-04-26       Impact factor: 6.085

6.  Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs.

Authors:  G Carles; D Braguer; C Dumontet; V Bourgarel; A Gonçalves; M Sarrazin; J B Rognoni; C Briand
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

Review 7.  Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?

Authors:  Daniele Fanale; Giuseppe Bronte; Francesco Passiglia; Valentina Calò; Marta Castiglia; Florinda Di Piazza; Nadia Barraco; Antonina Cangemi; Maria Teresa Catarella; Lavinia Insalaco; Angela Listì; Rossella Maragliano; Daniela Massihnia; Alessandro Perez; Francesca Toia; Giuseppe Cicero; Viviana Bazan
Journal:  Anal Cell Pathol (Amst)       Date:  2015-09-21       Impact factor: 2.916

8.  Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

Authors:  M Kobayashi; T Natsume; S Tamaoki; J Watanabe; H Asano; T Mikami; K Miyasaka; K Miyazaki; M Gondo; K Sakakibara; S Tsukagoshi
Journal:  Jpn J Cancer Res       Date:  1997-03

9.  Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

Authors:  T Natsume; J Watanabe; S Tamaoki; N Fujio; K Miyasaka; M Kobayashi
Journal:  Jpn J Cancer Res       Date:  2000-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.